- Home
- BOSC vs CYTH Comparison
BOSC vs CYTH Comparison
Compare BOSC & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOSC
- CYTH
- Stock Information
- Founded
- BOSC 1990
- CYTH 1990
- Country
- BOSC Israel
- CYTH United States
- Employees
- BOSC N/A
- CYTH N/A
- Industry
- BOSC Computer Communications Equipment
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- BOSC Telecommunications
- CYTH Health Care
- Exchange
- BOSC Nasdaq
- CYTH Nasdaq
- Market Cap
- BOSC 19.7M
- CYTH 20.4M
- IPO Year
- BOSC 1996
- CYTH N/A
- Fundamental
- Price
- BOSC $3.79
- CYTH $0.80
- Analyst Decision
- BOSC Strong Buy
- CYTH Buy
- Analyst Count
- BOSC 1
- CYTH 3
- Target Price
- BOSC $5.00
- CYTH $0.95
- AVG Volume (30 Days)
- BOSC 63.1K
- CYTH 55.3K
- Earning Date
- BOSC 11-27-2024
- CYTH 11-14-2024
- Dividend Yield
- BOSC N/A
- CYTH N/A
- EPS Growth
- BOSC 5.81
- CYTH N/A
- EPS
- BOSC 0.38
- CYTH N/A
- Revenue
- BOSC $40,448,000.00
- CYTH $870,725.00
- Revenue This Year
- BOSC $6.20
- CYTH N/A
- Revenue Next Year
- BOSC N/A
- CYTH $24.49
- P/E Ratio
- BOSC $9.97
- CYTH N/A
- Revenue Growth
- BOSC N/A
- CYTH N/A
- 52 Week Low
- BOSC $2.50
- CYTH $0.55
- 52 Week High
- BOSC $4.20
- CYTH $2.12
- Technical
- Relative Strength Index (RSI)
- BOSC 62.05
- CYTH 67.47
- Support Level
- BOSC $3.43
- CYTH $0.55
- Resistance Level
- BOSC $3.78
- CYTH $0.72
- Average True Range (ATR)
- BOSC 0.25
- CYTH 0.07
- MACD
- BOSC 0.02
- CYTH 0.02
- Stochastic Oscillator
- BOSC 60.85
- CYTH 92.59
About BOSC B.O.S. Better Online Solutions
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.